Mice are poor stand-ins for people in experiments on some types of inflammation, a new study concludes. But some scientists say that critique discounts the value of mouse studies, many of which simply couldn’t be done without the animals.
More attention — and money — should go toward studying disease in people than on mouse research, a consortium of scientists contends online February 11 in the Proceedings of the National Academy of Sciences. Too often, researchers make a discovery in mice and assume that humans will react in the same way, says study coauthor Ronald Tompkins, chief of the Massachusetts General Hospital burn service. “The presumption is not justifiable,” he says. As a result, drug trials — often based heavily on data gleaned from studies with mice — can fail.
But other scientists say that critique isn’t new and is overstated. Clinical trials are unsuccessful for many reasons, says Derry Roopenian, an immunologist and mouse geneticist at the Jackson Laboratory in Bar Harbor, Maine. “There’s frailty all along the process. That’s not a failure of the mouse.”
He and other critics worry that the study, conducted with a generic strain of laboratory mouse called Black6, unfairly tarnishes the reputation of all mice, even ones engineered to be as much like humans as possible. The group’s conclusions, were they accepted by policy makers, could set back biomedical research by jeopardizing funding for mouse studies, critics warn. “Without the mouse, progress is going to be slowed to a standstill,” Roopenian says.
Most of the researchers agree that creating mice with biologic responses that more closely mirror humans is important to understand diseases and develop new drugs. The sticking point appears to be how to balance mouse-based research with research involving humans.